2019
DOI: 10.1080/15592294.2019.1621139
|View full text |Cite
|
Sign up to set email alerts
|

aFARP-ChIP-seq, a convenient and reliable method for genome profiling in as few as 100 cells with a capability for multiplexing ChIP-seq

Abstract: Much effort has been devoted to understand how chromatin modification regulates development and disease. Despite recent progress, however, it remains difficult to obtain high-quality epigenomic maps using chromatin-immunoprecipitation-coupled deep sequencing (ChIP-seq) in samples with low-cell numbers. Here, we present an Atlantis dsDNase-based technology, aFARP-ChIPseq, that provides accurate profiling of genome-wide histone modifications in as few as 100 cells. By mapping histone lysine trimethylation (H3K4m… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2
1

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 50 publications
0
1
0
Order By: Relevance
“…We show that cTSA-seq can offer high quality mapping of chromatin at or near the NL in as few as 50 000 cells without adding any carriers. We have previously developed a carrier approach to reduce sample loss in low-cell ChIP-seq, and have successfully used this approach to map epigenetic marks and transcription factor binding sites from as few as 100 cells ( 43 , 44 ). Adapting this carrier approach to be compatible with cTSA-seq should enable mapping of chromatin regions at or near the NL in far fewer cells than 50 000, especially considering that these chromatin regions represents 30–50% of the genome.…”
Section: Resultsmentioning
confidence: 99%
“…We show that cTSA-seq can offer high quality mapping of chromatin at or near the NL in as few as 50 000 cells without adding any carriers. We have previously developed a carrier approach to reduce sample loss in low-cell ChIP-seq, and have successfully used this approach to map epigenetic marks and transcription factor binding sites from as few as 100 cells ( 43 , 44 ). Adapting this carrier approach to be compatible with cTSA-seq should enable mapping of chromatin regions at or near the NL in far fewer cells than 50 000, especially considering that these chromatin regions represents 30–50% of the genome.…”
Section: Resultsmentioning
confidence: 99%